Cited by 1,817PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase SignalingMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 101 of the 103 references it cites were found in a registry or an index.

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Open access

Mendoza, Michelle C., Er, E. Emrah, Blenis, John·2011·Trends in Biochemical Sciences

DOI 10.1016/j.tibs.2011.03.006PMC PMC3112285

Open this paper in CoChat — free account

Abstract

The Ras-extracellular signal-regulated kinase (Ras-ERK) and phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms for controlling cell survival, differentiation, proliferation, metabolism, and motility in response to extracellular cues. Components of these pathways were among the first to be discovered when scientists began cloning proto-oncogenes and purifying cellular kinase activities in the 1980s. Ras-ERK and PI3K-mTOR were originally modeled as linear signaling conduits activated by different stimuli, yet even early experiments hinted that they might intersect to regulate each other and co-regulate downstream functions. The extent of this cross-talk and its significance in cancer therapeutics are now becoming clear.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.tibs.2011.03.006

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL
Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,578
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms
Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., & Greenberg, M. E. (1999) · Science · doi:10.1126/science.286.5443.1358 · Cited by 1,908
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460

Flagged first, then by citations

Show all 103 references

2 of the 103 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 1,004

Co-operation between the AKT and ERK signaling pathways may support growth of deep endometriosis in a fibrotic microenvironment in vitro†
Matsuzaki, S., & Darcha, C. (2015) · Human Reproduction · doi:10.1093/humrep/dev108 · Cited by 89
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases
Kotian, S., Zhang, L., Boufraqech, M., Gaskins, K., Gara, S. K., Quezado, M., Nilubol, N., & Kebebew, E. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1043 · Cited by 88
Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
von Manstein, V., Yang, C., Richter, D. E., Delis, N., Vafaizadeh, V., & Groner, B. (2014) · Current Signal Transduction Therapy · doi:10.2174/1574362409666140206221931 · Cited by 88
Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells
Bernfeld, E., & Foster, D. A. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.03.003 · Cited by 85
The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions
Khorasani, A. B. S., Pourbagheri‐Sigaroodi, A., Pirsalehi, A., Safaroghli‐Azar, A., Zali, M. R., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173983 · Cited by 91
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
Garten, A., Grohmann, T., Kľučková, K., Lavery, G. G., Kieß, W., & Penke, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164048 · Cited by 86
Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways
Kaikai, S., Ji, L., Gong, C., Ma, Y., Yang, L., Fan, Y., Hou, M., & Wang, Z. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.05.024 · Cited by 88
Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers
Tulalamba, W., & Janvilisri, T. (2012) · International Journal of Cell Biology · doi:10.1155/2012/594681 · Cited by 86
Targeting β‐catenin in hepatocellular cancers induced by coexpression of mutant β‐catenin and K‐Ras in mice
Tao, J., Zhang, R., Singh, S., Poddar, M., Xu, E., Oertel, M., Chen, X., Ganesh, S., Abrams, M. T., & Monga, S. P. (2016) · Hepatology · doi:10.1002/hep.28975 · Cited by 85
Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress
Duan, Y., Haybaeck, J., & Yang, Z. (2020) · Cancers · doi:10.3390/cancers12102972 · Cited by 88
Trimethyltin-induced hippocampal neurodegeneration: A mechanism-based review.
Lee, S., Yang, M., Kim, J., Kang, S., Kim, J., Kim, J.-C., Jung, C., Shin, T., Kim, S.-H., & Moon, C. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.07.010 · Cited by 92
A Live-Cell Screen for Altered Erk Dynamics Reveals Principles of Proliferative Control
Goglia, A. G., Wilson, M. Z., Jena, S. G., Silbert, J., Basta, L. P., Devenport, D., & Toettcher, J. E. (2020) · Cell Systems · doi:10.1016/j.cels.2020.02.005 · Cited by 84
Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality
Kitagawa, M., Liao, P.-J., Lee, K. H., Wong, J., Shang, S. C., Minami, N., Sampetrean, O., Saya, H., Dai, L., Prabhu, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02287-5 · Cited by 84
Cannabidiol exerts protective effects in an in vitro model of Parkinson's disease activating AKT/mTOR pathway
Gugliandolo, A., Pollastro, F., Bramanti, P., & Mazzon, E. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104553 · Cited by 82
Molecular Mechanisms Underlying the Analgesic Property of Intrathecal Dexmedetomidine and Its Neurotoxicity Evaluation: An In Vivo and In Vitro Experimental Study
Zhang, H., Zhou, F., Li, C., Kong, M. K., Liu, H., Zhang, P., Zhang, S., Cao, J., Zhang, L., & Ma, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055556 · Cited by 82
Huang-Lian-Jie-Du-Decotion induced protective autophagy against the injury of cerebral ischemia/reperfusion via MAPK-mTOR signaling pathway
Wang, P., Wang, J., Zhang, C., Song, X., Tian, N., & Kong, L. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.06.035 · Cited by 82
mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)
Hu, K., Dai, H.-B., & Qiu, Z.-L. (2016) · Oncology Reports · doi:10.3892/or.2016.4922 · Cited by 82
CXCR4 Chemokine Receptor Signaling Induces Apoptosis in Acute Myeloid Leukemia Cells via Regulation of the Bcl-2 Family Members Bcl-XL, Noxa, and Bak
Kremer, K. N., Peterson, K. L., Schneider, P. A., Meng, X. W., Dai, H., Hess, A. D., Smith, B. D., Rodriguez-Ramirez, C., Karp, J. E., Kaufmann, S. H., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.449926 · Cited by 81
Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K/Akt and GRP78 Signaling on a Microfluidic Platform
Li, Y., Zhu, Z., Xu, Z., He, T., Li, E., Guo, Z., Liu, F., Jiang, C., & Wang, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129593 · Cited by 81
Translational regulation of the cell cycle: when, where, how and why?
Kronja, I., & Orr‐Weaver, T. L. (2011) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0084 · Cited by 86
A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa
Frew, J. W., Vekic, D. A., Woods, J. A., & Cains, G. D. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15441 · Cited by 81
Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing
Nakagaki, T., Tamura, M., Kobashi, K., Koyama, R., Fukushima, H., Ohashi, T., Idogawa, M., Ogi, K., Hiratsuka, H., Tokino, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19262 · Cited by 81
Regulation of the PI3K/Akt pathway during decidualization of endometrial stromal cells
Fabi, F., Grenier, K., Parent, S., Adam, P., Tardif, L., Leblanc, V., & Asselin, É. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177387 · Cited by 82
Amphiregulin potentiates airway inflammation and mucus hypersecretion induced by urban particulate matter via the EGFR-PI3Kα-AKT/ERK pathway
Wang, J., Zhu, M., Wang, L., Chen, C., & Song, Y. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.10.002 · Cited by 80
Piezo-type mechanosensitive ion channel component 1 (Piezo1) in human cancer
Yu, J., & Liao, H.-Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111692 · Cited by 81
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
Westin, S. N., Labrie, M., Litton, J. K., Blucher, A., Fang, Y., Vellano, C. P., Marszalek, J. R., Feng, N., Ma, X., Creason, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1656 · Cited by 84
Novel compounds for the modulation of mTOR and autophagy to treat neurodegenerative diseases
Heras-Sandoval, D., Pérez‐Rojas, J. M., & Pedraza‐Chaverrí, J. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109442 · Cited by 79
Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells
Lin, S., Zhang, X., Huang, G., Cheng, L., Lv, J., Zheng, D., Lin, S., Wang, S., Wu, Q., Long, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01605-4 · Cited by 81
Pre‐maturation with cAMP modulators in conjunction with EGF‐like peptides during in vitro maturation enhances mouse oocyte developmental competence
Richani, D., Wang, X., Zeng, H., Smitz, J. E. J., Thompson, J. G., & Gilchrist, R. B. (2014) · Molecular Reproduction and Development · doi:10.1002/mrd.22307 · Cited by 79
Comparison of anti-inflammatory mechanisms of mango (Mangifera Indica L.) and pomegranate (Punica Granatum L.) in a preclinical model of colitis
Kim, H., Banerjee, N., Ivanov, I., Pfent, C., Prudhomme, K. R., Bisson, W., Dashwood, R. H., Talcott, S., & Mertens-Talcott, S. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201501008 · Cited by 77
MAPK and PI3K signaling: At the crossroads of neural crest development
Dinsmore, C. J., & Soriano, P. M. (2018) · Developmental Biology · doi:10.1016/j.ydbio.2018.02.003 · Cited by 82
Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies
Yang, L., Zheng, L., Chng, W. J., & Ding, J. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.005 · Cited by 81
Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer
Mukherjee, S., Bhatti, G. K., Chhabra, R., Reddy, P. H., & Bhatti, J. S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114398 · Cited by 84
Integration of mTOR and estrogen–ERK2 signaling in lymphangioleiomyomatosis pathogenesis
Gu, X., Yu, J. J., Ilter, D., Blenis, N., Henske, E. P., & Blenis, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309110110 · Cited by 78
Self-citation
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Britten, C. D., Adjei, A. A., Millham, R., Houk, B. E., Borzillo, G. V., Pierce, K. J., Wainberg, Z. A., & LoRusso, P. M. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0062-5 · Cited by 79
Optogenetically controlled protein kinases for regulation of cellular signaling
Leopold, A. V., Chernov, K. G., & Verkhusha, V. V. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00404d · Cited by 79
A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation
Dingemans, A. C., Mellema, W. W., Groen, H. J. M., van Wijk, A. W., Burgers, S. A., Kunst, P. W. A., Thunnissen, E., Heideman, D. A. M., & Smit, E. F. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1779 · Cited by 77
Smarter drugs emerging in pancreatic cancer therapy
Kleger, A., Perkhofer, L., & Seufferlein, T. T. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu013 · Cited by 78
Cancers associated with human gammaherpesviruses
Wen, K. W., Wang, L., Menke, J. R., & Damania, B. (2021) · FEBS Journal · doi:10.1111/febs.16206 · Cited by 77
BET Proteins as Attractive Targets for Cancer Therapeutics
Sarnik, J., Popławski, T., & Tokarz, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011102 · Cited by 78
Multiplexed Fluorescence Imaging of ERK and Akt Activities and Cell-cycle Progression
Maryu, G., Matsuda, M., & Aoki, K. (2016) · Cell Structure and Function · doi:10.1247/csf.16007 · Cited by 76
Pilocytic astrocytomas
Bornhorst, M., Frappaz, D., & Packer, R. J. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00020-7 · Cited by 76
Cancer drug resistance: A fleet to conquer
Hussain, S., Singh, A., Nazir, S. U., Tulsyan, S., Khan, A., Kumar, R., Bashir, N., Tanwar, P., & Mehrotra, R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28782 · Cited by 80
LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma
Vieira, G. C., Chockalingam, S., Melegh, Z., Greenhough, A., Malik, S., Szemes, M., Park, J. H., Kaidi, A., Zhou, L., Catchpoole, D. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5548 · Cited by 75
NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer
Gambardella, V., Gimeno-Valiente, F., Tarazona, N., Martínez‐Ciarpaglini, C., Roda, D., Fleitas, T., Tolosa, P., Cejalvo, J. M., Huerta, M., Roselló, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2421 · Cited by 75
Therapeutics Targeting Mutant KRAS
Thein, K. Z., Biter, A. B., & Hong, D. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-033145 · Cited by 76
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis
Hendrikse, C. S. E., Theelen, P. M. M., van der Ploeg, P., Westgeest, H. M., Boere, I. A., Thijs, A. M. J., Ottevanger, P. B., van de Stolpe, A., Lambrechts, S., Bekkers, R. L. M., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.01.038 · Cited by 75
Pathological and Molecular Advances in Pediatric Low-Grade Astrocytoma
Rodríguez, F. J., Lim, K. S., Bowers, D. C., & Eberhart, C. G. (2012) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164009 · Cited by 76
Vinca alkaloid drugs promote stress-induced translational repression and stress granule formation
Szaflarski, W., Fay, M. M., Kedersha, N., Zabel, M., Anderson, P., & Ivanov, P. V. (2016) · Oncotarget · doi:10.18632/oncotarget.8728 · Cited by 75
Role of Insulin in Placental Transport of Nutrients in Gestational Diabetes Mellitus
Ruíz‐Palacios, M., Ruiz‐Alcaraz, A. J., Sánchez-Campillo, M., & Larqué, E. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000455904 · Cited by 83
Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
Bryan, M. C., & Rajapaksa, N. S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00667 · Cited by 75
RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact
Zaravinos, A., Bonavida, B., Chatzaki, Ε., & Baritaki, S. (2018) · Cancers · doi:10.3390/cancers10090287 · Cited by 75
Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient
Dazert, E., Colombi, M., Boldanova, T., Moes, S., Adametz, D., Quagliata, L., Röth, V., Terracciano, L., Heim, M. H., Jenoe, P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523434113 · Cited by 73
Emerging therapeutic targets for the treatment of malignant rhabdoid tumors
Nemes, K., & Frühwald, M. C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1451839 · Cited by 74
Integrating chemical and mechanical signals through dynamic coupling between cellular protrusions and pulsed ERK activation
Yang, J.-M., Bhattacharya, S., West‐Foyle, H., Hung, C., Wu, T. ‐., Iglesias, P. A., & Huang, C. (2018) · Nature Communications · doi:10.1038/s41467-018-07150-9 · Cited by 70
ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis
Ali, E. S., Sahu, U., Villa, E., O’Hara, B. P., Gao, P., Beaudet, C., Wood, A. W., Asara, J. M., & Ben‐Sahra, I. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.001 · Cited by 78
Targeting the MAPK/ERK and PI3K/AKT Signaling Pathways Affects NRF2, Trx and GSH Antioxidant Systems in Leukemia Cells
Jasek-Gajda, E., Jurkowska, H., Jasińska, M., & LIS, G. J. (2020) · Antioxidants · doi:10.3390/antiox9070633 · Cited by 73
A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma
Mlakar, V., Morel, E., Mlakar, S. J., Ansari, M., & Gumy‐Pause, F. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01967-x · Cited by 72
Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer
Lü, X., Li, Y., Li, X., & Aisa, H. A. (2017) · Oncology Letters · doi:10.3892/ol.2017.6380 · Cited by 76
Carvacrol induces cytotoxicity in human cervical cancer cells but causes cisplatin resistance: Involvement of MEK–ERK activation
Potočnjak, I., Gobin, I., & Domitrović, R. (2018) · Phytotherapy Research · doi:10.1002/ptr.6048 · Cited by 76
PI3K: A Crucial Piece in the RAS Signaling PuzzlePreprint
Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 79
The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor
Won, J., Yang, H. W., Shin, S., Lee, J., Heo, W. D., & Cho, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs021 · Cited by 75
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
Ebbesen, S. H., Scaltriti, M., Bialucha, C. U., Morse, N., Kastenhuber, E. R., Wen, H. Y., Dow, L. E., Baselga, J. M., & Lowe, S. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523693113 · Cited by 73
Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain
Antic, I., Biancucci, M., Zhu, Y., Gius, D. R., & Satchell, K. J. F. (2015) · Nature Communications · doi:10.1038/ncomms8396 · Cited by 72
Control of B lymphocyte development and functions by the mTOR signaling pathways
Iwata, T., Ramírez, J. A., Park, H., & Iritani, B. M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.005 · Cited by 73
A liposome/gelatin methacrylate nanocomposite hydrogel system for delivery of stromal cell-derived factor-1α and stimulation of cell migration
Yu, J. R., Janssen, M., Liang, B. J., Huang, H., & Fisher, J. P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.015 · Cited by 71
Splicing factors: Insights into their regulatory network in alternative splicing in cancer
Du, J.-X., Zhu, G., Cai, J., Wang, B., Luo, Y., Chen, C., Cai, C.-Z., Zhang, S., Zhou, J., Fan, J., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.043 · Cited by 72
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
Sweetlove, M., Wrightson, E., Kolekar, S., Rewcastle, G. W., Baguley, B. C., Shepherd, P. R., & Jamieson, S. M. F. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00135 · Cited by 71
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Vakana, E., Pratt, S. E., Blosser, W. D., Dowless, M. S., Simpson, N., Yuan, X., Jaken, S., Manro, J. R., Stephens, J. R., Zhang, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14002 · Cited by 72
PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma
Ma, H., Li, Y., Wang, X., Wu, H., Qi, G., Li, R., Yang, N., Gao, M., Shi, Y., Yuan, C., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1415-6 · Cited by 69
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70
MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells
Zhou, P., Huang, G., Zhao, Y., Zhong, D., Xu, Z., Zeng, Y., Zhang, Y., Li, S., & He, F. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.02.020 · Cited by 70
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling
Wang, Z., Fan, Z., Jiang, H., & Qu, J. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs367 · Cited by 70
Emerging therapeutic targets in metastatic progression: A focus on breast cancer
Li, Z., & Kang, Y. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.003 · Cited by 71
Signaling by FGF Receptor 2, Not FGF Receptor 1, Regulates Myelin Thickness through Activation of ERK1/2–MAPK, Which Promotes mTORC1 Activity in an Akt-Independent Manner
Furusho, M., Ishii, A., & Bansal, R. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3316-16.2017 · Cited by 72
EGFRvIII: An Oncogene with Ambiguous Role
Rutkowska, A., Stoczyńska-Fidelus, E., Janik, K., Włodarczyk, A., & Rieske, P. (2019) · Journal of Oncology · doi:10.1155/2019/1092587 · Cited by 71
The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors
Guimarães, L. M., Coura, B. P., Gomez, R. S., & Gomes, C. C. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.740788 · Cited by 72
Biphasic regulation of osteoblast development via the ERK MAPK–mTOR pathway
Kim, J., Yang, Y.-S., Hong, J., Chaugule, S. R., Chun, H., van der Meulen, M. C. H., Xu, R., Greenblatt, M. B., & Shim, J. (2022) · eLife · doi:10.7554/elife.78069 · Cited by 72
Antitumor Efficacy of α-Solanine against Pancreatic Cancer In Vitro and In Vivo
Lv, C., Kong, H., Dong, G., Liu, L., Tong, K., Sun, H., Chen, B., Zhang, C., & Zhou, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087868 · Cited by 69
Erk1/2 activation and modulation of STAT3 signaling in oral cancer
Gkouveris, I., Nikitakis, N. G., Karanikou, M., Rassidakis, G. Z., & Sklavounou, A. (2014) · Oncology Reports · doi:10.3892/or.2014.3440 · Cited by 68
mTOR: A Link from the Extracellular Milieu to Transcriptional Regulation of Oligodendrocyte Development
Wood, T. L., Bercury, K. K., Cifelli, S. E., Mursch, L. E., Min, J., Dai, J., & Macklin, W. B. (2013) · ASN NEURO · doi:10.1042/an20120092 · Cited by 69
Apigenin Reduces Survival of Choriocarcinoma Cells by Inducing Apoptosis via the PI3K/AKT and ERK1/2 MAPK Pathways
Lim, W., Park, S., Bazer, F. W., & Song, G. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25372 · Cited by 69
Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer
Bellazzo, A., Minin, G. D., & Collavin, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.134 · Cited by 74
Impairment of object recognition memory by rapamycin inhibition of mTOR in the amygdala or hippocampus around the time of learning or reactivation
Jobim, P. F. C., Pedroso, T. R., Werenicz, A., Christoff, R. R., Maurmann, N., Reolon, G. K., Schröder, N., & Roesler, R. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.004 · Cited by 68
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66
Acquisition of anoikis resistance promotes alterations in the Ras/ERK and PI3K/Akt signaling pathways and matrix remodeling in endothelial cells
Mesquita, A. P. D. S., Lopes, S. D. A., Filho, P. C. A. P., Nader, H. B., & Lopes, C. C. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1392-0 · Cited by 68
PI3K in stemness regulation: from development to cancer
Madsen, R. R. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190778 · Cited by 69
A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
Tian, Y., & Guo, W. (2020) · Medical Science Monitor · doi:10.12659/msm.920957 · Cited by 71
The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis
Qi, C., Huang, M., Zou, Y., Yang, R., Jiang, Y., Sheng, J., Kong, Y., Tao, Z., Feng, H., Hua, Q., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02191-3 · Cited by 68
Raf Inhibitors Target Ras Spatiotemporal Dynamics
Cho, K.-J., Kasai, R. S., Park, J.-H., Chigurupati, S., Heidorn, S. J., van der Hoeven, D., Plowman, S. J., Kusumi, A., Marais, R., & Hancock, J. F. (2012) · Current Biology · doi:10.1016/j.cub.2012.03.067 · Cited by 68
The free fatty acid receptor 1 promotes airway smooth muscle cell proliferation through MEK/ERK and PI3K/Akt signaling pathways
Matoba, A., Matsuyama, N., Shibata, S., Masaki, E., Emala, C. W., & Mizuta, K. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00129.2017 · Cited by 70
LncRNA ST3Gal6‐AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α‐2,3 sialylation via PI3K/Akt signaling
Hu, J., Shan, Y., Ma, J., Pan, Y., Zhou, H., Jiang, L., & Li, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32103 · Cited by 70
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
Li, X., Su, Y., Madlambayan, G. J., Edwards, H. J., Polin, L., Kushner, J., Dzinic, S. H., White, K., Ma, J., Knight, T. E., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.201343 · Cited by 66
Intercellular Transfer of Oncogenic KRAS via Tunneling Nanotubes Introduces Intracellular Mutational Heterogeneity in Colon Cancer Cells
Desir, S., Wong, P., Turbyville, T. J., Chen, D., Shetty, M., Clark, C., Zhai, E., Romin, Y., Manova-Todorova, K. O., Starr, T. K., et al. (2019) · Cancers · doi:10.3390/cancers11070892 · Cited by 69
Angiotensin type 2 receptor activation promotes browning of white adipose tissue and brown adipogenesis
Than, A., Xu, S., Li, R., Leow, M. K., Sun, L., & Chen, P. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.22 · Cited by 69
Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs
Saqcena, M., Mukhopadhyay, S., Hosny, C., Alhamed, A., Chatterjee, A., & Foster, D. A. (2015) · Oncogene · doi:10.1038/onc.2014.207 · Cited by 67
Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials
Li, X., Dai, D., Chen, B., Tang, H., Xie, X., & Wei, W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192464 · Cited by 66
Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells
El‐Mashtoly, S. F., Yosef, H. K., Petersen, D., Mavarani, L., Maghnouj, A., Hahn, S. A., Kötting, C., & Gerwert, K. B. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01431 · Cited by 65
Human MAF1 targets and represses active RNA polymerase III genes by preventing recruitment rather than inducing long-term transcriptional arrestPreprint
Orioli, A., Praz, V., Lhôte, P., & Hernandez, N. (2016) · Genome Research · doi:10.1101/gr.201400.115 · Cited by 67
SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor
Chiang, C., Pan, C., Chang, H., Lai, M.-D., Tzai, T., Tsai, Y., Ling, P., Liu, H., Lee, B., Cheng, H.-L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3308 · Cited by 64

Authors: Mendoza, M. C., Er, E. E., & Blenis, J.
Affiliations: Harvard University (US)
Corresponding author: Blenis, John
ORCID: Mendoza, Michelle C.
Er, E. Emrah
Blenis, John
Venue: Trends in Biochemical Sciences
Publisher: Elsevier BV
Published: 2011-06
Volume: 36
Issue: 6
Pages: 320-328
ISSN: 0968-0004 (ISSN-L)
DOI: 10.1016/j.tibs.2011.03.006
PMC: PMC3112285
OpenAlex: W1998203489
Cited by: 1,817
References: 103
Citations by year: 2026: 112 · 2025: 96 · 2024: 122 · 2023: 133 · 2022: 127 · 2021: 163 · 2020: 166 · 2019: 164 · 2018: 144 · 2017: 158 · 2016: 123 · 2015: 100 · 2014: 92 · 2013: 55 · 2012: 49
FWCI: 5.82
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Trends in Biochemical Sciences (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: LAM Foundation
Susan G. Komen
National Cancer Institute (R37CA046595)
National Institute of General Medical Sciences (R01GM051405)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: Ras/ERK signaling pathway, signaling crosstalk, cell survival, cell proliferation, cell differentiation, cellular metabolism, cell motility, proto-oncogenes, cancer therapeutics
MeSH terms: Humans, Signal Transduction, ras Proteins, Extracellular Signal-Regulated MAP Kinases, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks